Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Community-acquired pneumonia

H A Cassiere1, M S Niederman

  • 1State University of New York at Stony Brook.

Disease-A-Month : DM
|December 22, 1998
PubMed
Summary
This summary is machine-generated.

Community-acquired pneumonia (CAP) management is evolving, especially for the elderly. Current approaches focus on patient factors like age and comorbidities for risk stratification and empiric antibiotic therapy, adapting to changing clinical pictures and resistance patterns.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspiration pneumonia.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
Same author

Multi-drug resistant organism infections in a medical ICU: Association to clinical features and impact upon outcome.

Medicina intensiva·2017
Same author

An Economic Model to Compare the Different Empiric and First/Second Line Treatment Regimens for Suspected Methicillin-Resistant Staphylococcus Aureus Nosocomial Pneumonia.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Response to "Treatment guidelines for nosocomial pneumonia: Agreeing to disagree".

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same author

Initial antimicrobial treatment of hospital acquired pneumonia in adults: A conference report.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses·2012
Same author

Fluoroquinolones in the management of community-acquired pneumonia.

International journal of clinical practice·2010
Same journal

Disturbances due to cold.

Disease-a-month : DM·2026
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
See all related articles

Area of Science:

  • Pulmonology and Infectious Diseases
  • Internal Medicine
  • Geriatrics

Background:

  • Community-acquired pneumonia (CAP) remains a major cause of illness and death, particularly in the growing elderly population.
  • The clinical presentation of CAP is shifting due to an aging demographic, necessitating updated diagnostic and treatment strategies.
  • Traditional typical vs. atypical classification is replaced by categorization based on patient age, comorbidities, and pneumonia severity.

Purpose of the Study:

  • To reassess and update the approach to diagnosing and managing community-acquired pneumonia (CAP) in light of an aging population.
  • To outline current strategies for risk stratification, diagnostic evaluation, and empiric antimicrobial therapy for CAP patients.
  • To address challenges in CAP management, including bacterial resistance and delayed radiographic resolution.

Related Experiment Videos

Main Methods:

  • Stratification of CAP patients by age, comorbidities, and severity to determine mortality risk and guide therapy location (outpatient, inpatient, ICU).
  • Emphasis on a limited role for diagnostic tests and procedures in the work-up of pneumonia.
  • Empiric antibiotic selection based on patient demographics, coexisting medical conditions, and pneumonia severity, with adjustments for identified pathogens or resistance.

Main Results:

  • Radiographic resolution of CAP is significantly influenced by patient age and the number of lung lobes involved, decreasing with age and multilobar disease.
  • Advanced age and comorbidities like diabetes, renal disease, and COPD negatively impact pneumonia resolution.
  • Empiric antibiotic therapy is standard when pathogens are unidentified, with potential for spectrum narrowing upon pathogen identification.

Conclusions:

  • The management of CAP requires a dynamic, individualized approach considering patient-specific factors and evolving resistance patterns.
  • Delayed radiographic resolution is common in elderly patients and those with comorbidities, with specific factors influencing diagnostic work-up.
  • Current guidelines favor empiric antibiotic therapy, adapting treatment based on epidemiological data and pathogen identification.